Compare DRUG · QFN · FTEC · MVB · ATEC
DRUG, QFN, FTEC, MVB and ATEC hold at least 199 companies between them. None is in every one of them, and QFN and MVB are the most alike: 71.5% of each is the same companies.
We can see through 99.2% of these funds to individual companies. The rest is cash, bonds, or a fund whose holdings we cannot see, so every figure here is a floor.
Return, last year
Price only, last year, each fund starting at 100. No fund here paid a distribution in this window.
Side by side
| DRUG | QFN | FTEC | MVB | ATEC | |
|---|---|---|---|---|---|
| Fund | BetaShares | BetaShares | Global X | VanEck | BetaShares |
| Asset class | Sector & thematic | Sector & thematic | Sector & thematic | Sector & thematic | Sector & thematic |
| Fee a year | 0.57% | 0.34% | 0.69% | 0.28% | 0.48% |
| Fund size | $163.0m | $80.0m | $4.3m | $279.0m | $613.6m |
| Holdings | 66 | 29 | 76 | 8 | 44 |
| 1Y price return | +6.2% | −4.2% | -- | −3.5% | +0.4%only priced since 2026-09-24 |
| Distribution yield | 3.96% | 2.19% | Not yet | 4.47% | 1.93% |
| Look-through coverage | 99.7% | 98.5% | 98.3% | 100.0% | 99.7% |
Holdings, fund by fund
- Financials
- Health Care
- Information Technology
- Industrials
- Communication Services
- Everything else
- Bonds
- Cash
- CBACOMMONWEALTH BANK OF AUSTRALIA.In 2 of 5DRUGnot heldQFN28.7%FTECnot heldMVB19.2%ATECnot held
- ANZANZ GROUP HOLDINGS LIMITEDIn 2 of 5DRUGnot heldQFN13.3%FTECnot heldMVB20.7%ATECnot held
- NABNATIONAL AUSTRALIA BANK LIMITEDIn 2 of 5DRUGnot heldQFN14.0%FTECnot heldMVB20.2%ATECnot held
- WBCWESTPAC BANKING CORPORATIONIn 2 of 5DRUGnot heldQFN13.7%FTECnot heldMVB20.2%ATECnot held
- MQGMACQUARIE GROUP LIMITEDIn 2 of 5DRUGnot heldQFN10.2%FTECnot heldMVB17.5%ATECnot held
- CPUCOMPUTERSHARE LIMITED.In 1 of 5DRUGnot heldQFNnot heldFTECnot heldMVBnot heldATEC10.5%
- LLYELI LILLY & COIn 1 of 5DRUG8.3%QFNnot heldFTECnot heldMVBnot heldATECnot held
- XROXERO LIMITEDIn 2 of 5DRUGnot heldQFNnot heldFTEC1.1%MVBnot heldATEC8.2%
- JNJJOHNSON & JOHNSONIn 1 of 5DRUG8.1%QFNnot heldFTECnot heldMVBnot heldATECnot held
- PMEPRO MEDICUS LIMITEDIn 1 of 5DRUGnot heldQFNnot heldFTECnot heldMVBnot heldATEC8.0%
What each fund is in
Each figure is the company's weight inside that fund, so the funds are read against each other and nothing is added up. A company listed on two exchanges counts once in a fund. Each bar in the mix is one fund as 100% of itself. The striped colours are money we cannot see inside a company (cash, bonds, a fund we cannot open). Cash, bonds and funds we cannot open that come to under 1% of a bar are in Everything else.
What DRUG already gives you
- DRUG and ATEC share 0 companies0.0%
- DRUG and FTEC share 0 companies0.0%A floor, not a measurement: one of these funds is not fully resolved to individual companies.
- DRUG and MVB share 0 companies0.0%
- DRUG and QFN share 0 companies0.0%A floor, not a measurement: one of these funds is not fully resolved to individual companies.
- QFN and MVB share 7 companies71.5%A floor, not a measurement: one of these funds is not fully resolved to individual companies.
- FTEC and ATEC share 1 company1.1%A floor, not a measurement: one of these funds is not fully resolved to individual companies.
Show the other 4
- FTEC and MVB share 0 companies0.0%A floor, not a measurement: one of these funds is not fully resolved to individual companies.
- MVB and ATEC share 0 companies0.0%
- QFN and ATEC share 0 companies0.0%A floor, not a measurement: one of these funds is not fully resolved to individual companies.
- QFN and FTEC share 0 companies0.0%A floor, not a measurement: one of these funds is not fully resolved to individual companies.
Overlap is the smaller weight in every company both funds hold: the share of each fund the other already covers. Grouped by company, so a listing on two exchanges is one holding.
What each fund changed
Reading the holdings history…
Holdings are published monthly, so this is the last publication, not this week. A re-weight counts once it moves 0.25 points of the fund or more — below that, weights are just prices moving.